253 related articles for article (PubMed ID: 31627700)
1. Uncommon EGFR Mutations in Non-Small Cell Lung Cancer and Their Impact on the Treatment.
Bílek O; Holánek M; Berkovcová J; Horký O; Kazda T; Čoupková H; Špelda S; Kristková L; Zvaríková M; Podhorec J; Bořilová S; Bohovicová L; Zdražilová Dubská L
Klin Onkol; 2019; 32(Supplementum 3):6-12. PubMed ID: 31627700
[TBL] [Abstract][Full Text] [Related]
2. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
Čoupková H; Vyzula R
Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
[TBL] [Abstract][Full Text] [Related]
4. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
6. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic characteristics and outcome of patients with different EGFR mutations.
Zhou S; Hu X; Wang Y; Li J; Zhou L; Hao X; Liu Y; Shi Y
Asia Pac J Clin Oncol; 2019 Jun; 15(3):166-171. PubMed ID: 30311393
[TBL] [Abstract][Full Text] [Related]
8. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal.
Gristina V; Malapelle U; Galvano A; Pisapia P; Pepe F; Rolfo C; Tortorici S; Bazan V; Troncone G; Russo A
Cancer Treat Rev; 2020 Apr; 85():101994. PubMed ID: 32113081
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
[TBL] [Abstract][Full Text] [Related]
10. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
[TBL] [Abstract][Full Text] [Related]
11. Current management of uncommon EGFR mutations in non-small cell lung cancer.
Trinh JQ; Abughanimeh O
Curr Probl Cancer; 2024 Apr; 49():101064. PubMed ID: 38311523
[TBL] [Abstract][Full Text] [Related]
12. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
[TBL] [Abstract][Full Text] [Related]
13. [A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer
with Uncommon EGFR Mutations].
Du W; Wo Y; Lu T; Wang Y; Jiao W
Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):590-599. PubMed ID: 31526464
[TBL] [Abstract][Full Text] [Related]
14. The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer.
Karachaliou N; Molina-Vila MA; Rosell R
Expert Rev Respir Med; 2015 Jun; 9(3):241-4. PubMed ID: 25994105
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor mutations in non-small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction-based assays.
Shen CI; Ho HL; Yeh YC; Chiu CH; Chou TY
J Chin Med Assoc; 2020 Apr; 83(4):345-349. PubMed ID: 32101894
[TBL] [Abstract][Full Text] [Related]
16. First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.
Yu X; Zhang X; Zhang Z; Lin Y; Wen Y; Chen Y; Wang W; Zhang L
Cancer Commun (Lond); 2018 Jul; 38(1):51. PubMed ID: 30055651
[TBL] [Abstract][Full Text] [Related]
17. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.
De Luca A; Normanno N
Curr Drug Targets; 2010 Jul; 11(7):851-64. PubMed ID: 20388064
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
Pilotto S; Rossi A; Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Spitaleri G; Bria E; Novello S
Clin Lung Cancer; 2018 Jan; 19(1):93-104. PubMed ID: 28645631
[TBL] [Abstract][Full Text] [Related]
19. Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.
Sousa AC; Silveira C; Janeiro A; Malveiro S; Oliveira AR; Felizardo M; Nogueira F; Teixeira E; Martins J; Carmo-Fonseca M
Lung Cancer; 2020 Jan; 139():35-40. PubMed ID: 31715539
[TBL] [Abstract][Full Text] [Related]
20. Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma - Interlaboratory Quality Assessment in the Czech Republic.
Linda Č; Markéta K; Ivana T; Eva P; Milada M; Hana V; Ondřej H; Karolína B; Jiří D; Monika B; Pavel D
Klin Onkol; 2018; 31(5):353-360. PubMed ID: 30541321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
